Overview

ANF-Rho in the Treatment of Chronic Neutropenia

Status:
Withdrawn

Trial end date:
2016-10-01

Target enrollment:
0

Participant gender:
All

Summary

A 6 month safety, tolerability, efficacy and pharmacokinetic study with ANF-Rho to treat patients with chronic neutropenia.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Prolong Pharmaceuticals

Criteria

Inclusion Criteria:

1. Patients 1 years of age or older

2. Patients with established chronic neutropenia defined as Median Absolute Neutrophil
Count (ANC) < 0.5 x 109/L (both with and without demonstrated genetic lesion) having
an indication for treatment, including:

Independent of hematological parameters, all patients with: Shwachman-Diamond syndrome
(SDS), Barth's syndrome or other inherited diseases associated with neutropenia
(exclude Glycogen Storage Disease 1b)

3. Patients on granulocyte-colony stimulating factor (GCSF) & PEG-GCSF treatment are
still eligible to participate after a washout period of 7 days, after the stopping of
the drug

4. Signed and dated informed written consent/assent by the patient/parent

5. Women of childbearing potential with a negative serum pregnancy test and using a
reliable method of contraception during the study period. Male study participants also
agreeing to use contraception for the study period.

Exclusion Criteria:

1. Evidence of chromosomal abnormalities, myelodysplasia, hematologic malignancy,
aplastic anemia, systemic lupus erythematosus, or rheumatoid arthritis (Felty's
syndrome) or if the neutropenia was drug-induced

2. Progressive malignant disease or malignancy history

3. Presence of macrophage activation syndrome before the diagnosis of neutropenia

4. Clinical Significant Abnormal Renal, Cardiac, Hepatic or Blood Coagulation disease.

5. Chronic infection such as hepatitis B virus (HBV), hepatitis C Virus (HCV) or Human
immunodeficiency virus( HIV) or history of tuberculosis

6. Association with anemia, thrombocytopenia (low blood platelets) before the diagnosis
of neutropenia.

7. Drug abuse, substance abuse, or alcohol abuse

8. Use of any other investigational drug at the time of enrollment, or within 5
half-lives prior to enrollment, whichever is longer

9. Patients unwilling and/or who are not capable of ensuring compliance with the
provisions of the study protocol

10. Women who are pregnant or breastfeeding

11. Women of childbearing potential who do not use an approved method of birth control.
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods)
is not acceptable

12. Patients with known DNA loss-of-function mutations in GCSFR and RUNX1 genes